In early-stage B-cell chronic lymphocytic leukemia (B-CLL), vaccination with allogeneic DCs pulsed with tumor lysates or apoptotic bodies has been demonstrated as both feasible and safe, eliciting specific cytotoxic T lymphocyte responses against RHAMM [106]. The gene discussed is HMMR; the disease is B-cell chronic lymphocytic leukemia.